Navigation Links
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Date:7/11/2014

MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that Health Canada approved APTIOMTM (eslicarbazepine acetate) for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy.  APTIOMTM is not indicated for use in patients under 18 years of age.

Epilepsy is one of the most common neurological disorders and according to Epilepsy Canada, it affects 0.6% of the population and each year approximately 15,500 people learn they have epilepsy.  Partial-onset seizures are the most prevalent seizure type, accounting for 60% of new epilepsy diagnoses1 and approximately one third of patients do not have adequate seizure control5.

The approval of APTIOMTM is based on three Phase 3 randomized, double-blind, placebo-controlled, safety and efficacy trials (Studies BIA-2093-301, BIA-2093-302 and BIA-2093-304), which included more than 1,400 people living with partial-onset seizures inadequately controlled by one to three concomitant AEDs (including carbamazepine, lamotrigine, valproic acid and levetiracetam). In these global studies,  treatment with APTIOMTM demonstrated statistically significant reductions in standardized seizure frequency versus placebo, and significantly more APTIOMTM treated patients experienced seizure frequency reduction of 50% or more from baseline (41% compared to 22% for placebo-treated patients).

The most frequently reported adverse reactions in patients taking APTIOMTM were dizziness, somnolence, headache, nausea, diplopia, vomiting, fatigue, ataxia, vision blurred, and vertigo.

"The approval of APTIOMTM is an important milestone not only for our company, but for thousands of Canadians living with, and affected by epile
'/>"/>

SOURCE Sunovion Pharmaceuticals Canada Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
2. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
3. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
8. Avanir Pharmaceuticals to Participate in Two Conferences in December
9. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
10. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
11. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Prominent academics, leaders of the biopharmaceutical ... 3rd at Genetic Rx, a networking conference of ... place at the Joseph B. Martin Conference Center ... present and future of genetic medicines—including siRNA, ASOs, ... well as the treatment of patients with rare ...
(Date:11/22/2014)... RURO, Inc., a leading LIMS, RFID ... version 5.1.4. , RURO’s deployment teams have been ... in RURO’s 8 year history. Many deployments have ... version 5.1.4 is the perfect example – the ... , Limfinity® 5.1.4 release highlights – more than ...
(Date:11/22/2014)... November 22, 2014 The “Chiral ... Preparative), by Material (Metal, Glass, Plastic), by Application ... SFC] - Forecast to 2018” analyses and studies ... in North America, Europe, Asia, and Rest of ... and 15 figures spread through 135 pages and ...
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5Viruses' Advantage of Surprise is Lost 2
... Silence Therapeutics plc,(AIM: SLN) today announces a collaboration ... a range of novel approaches for the delivery,of ... leading,expertise in the delivery of siRNA molecules, in ... siRNA in vivo using its,proprietary AtuPLEX technology. The ...
... Therapeutics, Inc.,( http://www.proteontherapeutics.com ), a privately held ... the,medical needs of patients with kidney and ... seasoned biopharmaceutical executive, to the Company,s,Board of ... years of executive,leadership and experience in the ...
... for Monday, March 17th at 11:30am ET, NEW ... ) today announced that I. Craig Henderson, MD, the,Company,s ... Affairs, are scheduled to present at the Cowen and ... presentation, which will take place on Monday, March 17th ...
Cached Biology Technology:Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 2Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 3Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors 2Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference 2
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
(Date:11/6/2014)... -- A groundbreaking paper from a team of Florida ... of how plants could adapt to and survive environmental ... published in the latest issue of the journal ... (the complex of DNA and proteins) is organized in ... that some genes are turned on and others are ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2
... Mich. We are all aware of the health benefits ... do we metabolize it? Research at the University of ... and institutions in Canada and Sweden, has begun to uncover ... in fruits and vegetables. Trillions of bacteria live in ...
... a scarred heart cannot beat the way it used to, ... heart, at least. A team of University of Michigan ... colonies of beating heart cells. Their findings could advance the ... attack. Previous work in direct reprogramming, jumping straight from ...
... in twenty years with the current poaching rates. The loss of ... have tremendous effects on the ecosystems they now live in. ... are key drivers of ecosystem functioning because theyre not controlled by ... Beest, published in Journal of Ecology , highlights the role ...
Cached Biology News:U-M scientists & colleagues investigate the fiber of our being 2Help for a scarred heart: Scarring cells turned to beating muscle 2Poaching threatens savannah ecosystems 2
...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
... Activation of ICE-family proteases/caspases initiates apoptosis in ... Apoptosis Detection Kit provides a simple and ... by flow cytometry in intact cells. ... two aspartate residues linked to rhodamine 110 ...
Biology Products: